logo
Quick Facts
  

Why RYVYL Is Falling In Pre-market?

By RTTNews Staff Writer   ✉   | Published: | Follow Us On Google News

RYVYL Inc. (RVYL) announced the cancellation of the proposed underwritten public offering of shares of its common stock originally announced on April 15, 2024. The company said the cancellation results from an assessment by management that current market pricing is not conducive for an offering that would be in the best interests of the company or its stockholders.

RYVYL Inc.'s blockchain ledger-based platform offers a payment experience tailored for the global market.

Shares of RYVYL Inc. are down 25% in pre-market trade on Tuesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units
Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit.
TJX Companies Guides Q2 EPS Below Estimates; Boosts FY24 EPS Outlook - Update
While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings...
Target Q1 Profit Misses Estimates, Backs FY24 View; Stock Down
Target Corp. shares were losing more than 8 percent in pre-market activity on the NYSE after the general merchandise retailer reported weak profit, sales and comparable sales in its first quarter. Earnings per share missed the Street estimates. Further, the company issued second-quarter outlook and maintained fiscal 2024 forecast.
Biotechnology Weekly Update - May 21, 2024

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Latest Updates on COVID-19
Read More
COVID-19: Drugs in Development
RELATED NEWS
Follow RTT
Copyright © 2024 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap